Business · 09/10/2026
European Medicines Agency Approves Modification to Paediatric Investigation Plan for Fabhalta and Iptacopan
The European Medicines Agency has made a decision on a modification to a Paediatric Investigation Plan (PIP) for Fabhalta and Iptacopan, a treatment for Renal and urinary disorders, following an application for change to the existing plan.